The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions
RNA-seq (gene expression) · human · 417 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Ovarian cancerThis series is part of our curated briefing on it.
- Samples
- 417 samples: 417 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactionsCancer cell · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE276935_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1159767 and SRA study SRP532077. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from the first 400 of 417 sample titles: 400 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8509173 80Omentum001CD20
- GSM8509174 80Omentum001Immune
- GSM8509175 80Omentum002Tumor
- GSM8509176 80Omentum002Stroma
- GSM8509177 80Omentum003CD20
- GSM8509178 80Omentum003Immune
- GSM8509179 80Omentum003Tumor
- GSM8509180 80Omentum003Stroma
- GSM8509181 80Omentum004CD20
- GSM8509182 80Omentum004Immune
- GSM8509183 80Omentum004Tumor
- GSM8509184 80Omentum004Stroma
- GSM8509185 80Omentum005Stroma
- GSM8509186 80Omentum006Tumor
- GSM8509187 80Omentum006Stroma
- GSM8509188 80Omentum007CD20
- GSM8509189 80Omentum007Immune
- GSM8509190 80Omentum007Tumor
- GSM8509191 80Omentum007Stroma
- GSM8509192 80Omentum008CD20
- GSM8509193 80Omentum008Immune
- GSM8509194 80Omentum008Stroma
- GSM8509195 80Omentum009Tumor
- GSM8509196 80Omentum009Stroma
- GSM8509197 41Ovary001CD20
- GSM8509198 41Ovary001Immune
- GSM8509199 41Ovary001Stroma
- GSM8509200 41Ovary002Tumor
- GSM8509201 41Ovary002Stroma
- GSM8509202 41Ovary003CD20
- GSM8509203 41Ovary003Immune
- GSM8509204 41Ovary003Tumor
- GSM8509205 41Ovary003Stroma
- GSM8509206 41Ovary004Stroma
- GSM8509207 41Ovary005Stroma
- GSM8509208 41Ovary006CD20
- GSM8509209 41Ovary006Immune
- GSM8509210 41Ovary006Tumor
- GSM8509211 41Ovary006Stroma
- GSM8509212 41Ovary007CD20
+ 377 more — browse all 417 samples with per-sample file links →
- GSE268514 Integrative genomic analysis of Korean high-grade serous ovarian cancer 161 samples same disease briefing · shares ovarian
- GSE311212 Transcriptomic profiling in human ovarian cancer cell line OVCAR-3 following CDK2 inhibitor treatment 6 samples same disease briefing · shares ovarian
- GSE154600 Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma 5 samples same disease briefing · shares ovarian
- GSE128098 TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target 4 samples same disease briefing · shares ovarian
- GSE57477 Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes 72 samples same disease briefing · shares ovarian
- GSE314300 Rb CUT&RUN profiling in ovarian cancer cell lines following CDK2 inhibitor treatment 10 samples same disease briefing · shares ovarian
- GSE135242 Hi-C identifies structural variation associated with resistance in paired patient-derived ovarian cancer models 8 samples same disease briefing · shares ovarian
- GSE28330 Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents 107 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.